LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) unveiled significant findings from its Phase 3 IMPALA-2 clinical trial of molgramostim during two poster presentations at the ATS International Conference 2025. The new data underscores molgramostim’s potential to improve outcomes for patients with autoimmune pulmonary alveolar proteinosis (aPAP), a rare and debilitating lung disorder.
The first presentation, led by Dr. Tisha S. Wang of UCLA, highlighted molgramostim’s impact on reducing pulmonary surfactant burden, as evidenced by ground-glass opacification (GGO) scores. Over 24 weeks, patients treated with molgramostim experienced a greater decline in GGO scores compared to those on placebo (-2.1 vs. -1.1; P=0.0004). Additionally, fewer patients in the molgramostim group required rescue whole lung lavages (WLL), a common and invasive treatment for aPAP. Only 6 patients (7.4%) in the molgramostim group underwent WLLs during the 48-week study period compared to 11 patients (13.3%) in the placebo group.
“Molgramostim’s ability to reduce surfactant burden addresses the core cause of aPAP and marks a meaningful advance in treatment strategies,” the researchers concluded.
A second presentation by Dr. Ali Ataya of the University of Florida spotlighted the therapy’s impact on patient-reported outcomes, including respiratory health-related quality of life (HRQoL). Molgramostim patients reported significant improvements in breathing, daily physical activity, and overall health across multiple evaluative measures such as the St. George’s Respiratory Questionnaire (SGRQ) and EQ-5D-5L tool. Notably, improvements in SGRQ Impact scores (P=0.0084) and physical activity levels at Week 24 (P=0.0368) and Week 48 (P=0.0193) underscored the therapy’s promise in enhancing day-to-day living for patients.
“These findings reinforce molgramostim’s potential as a transformative treatment for aPAP—not only reducing disease severity but also significantly improving patients’ quality of life,” Savara stated in its announcement.
The findings were published in a supplement of the American Journal of Respiratory and Critical Care Medicine. Molgramostim’s promising data positions it as a compelling treatment option aimed at addressing both the physiological and experiential dimensions of aPAP.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.